Urokinase biosimilar - Sedico

Drug Profile

Urokinase biosimilar - Sedico

Alternative Names: Angikinase

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sedico
  • Class Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary thrombosis; Myocardial infarction; Pulmonary embolism; Thromboembolism

Most Recent Events

  • 03 Mar 2014 Launched prior to March 2014 for Coronary thrombosis in Egypt (Intracoronary)
  • 03 Mar 2014 Launched prior to March 2014 for Myocardial infarction in Egypt (Intracoronary)
  • 03 Mar 2014 Launched prior to March 2014 for Pulmonary embolism in Egypt (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top